[صفحه اصلی ]   [Archive]  
:: صفحه اصلي :: درباره نشريه :: آخرين شماره :: تمام شماره‌ها :: جستجو :: ثبت نام :: ارسال مقاله :: تماس با ما ::
:: دوره 12، شماره 3 - ( 1-1400 ) ::
جلد 12 شماره 3 صفحات 263-274 برگشت به فهرست نسخه ها
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
چکیده:   (226 مشاهده)
Background: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolideR, 0.5 mg in Iranian MS patients during one-year follow-up.
Methods: A multicenter, open-label, longitudinal was designed to evaluate the safety and efficacy of fingolideR, 0.5 mg over a one-year follow-up period across 11 centers. The patients were visited by their neurologists every two months to evaluate possible adverse events and clinical disease activity considered by recording Kurtzke’s Expanded Disability Status Scale (EDSS).
Results: A total of 252 patients with the mean treatment duration of 343±45.70 days were. 20 patients experienced adverse events (AEs) and serious adverse events (SAEs) such as resistant urinary tract infection (UTI), premature atrial contraction (PAC), skin allergic reaction, macular edema, chicken pox, zona, panic attacks, and exacerbations associated with steroids treatment, all of which led to FingolideR discontinuation. The mean EDSS decreased from (2.15±1.29, 95%CI: 1.99to2.32) at baseline to (1.85±1.22, 95%CI: 1.68to2.02) at 12th month (final visit) while a p-value revealed significant differences comparing baseline and final EDSS (p<0.001). Mean annualized relapse rate (ARR) of the patients in one year prior to the study was (0.006±0.016, 95%CI: 0.004to0.008) which changed to (0.005±0.016, 95%CI: 0.003to0.007) at the end of the study period. Patients with a 12-month period of fingolideR treatment experienced sustained ARR and disease progression (p<0.001).
Conclusion: The obtained findings suggest that the administration of FingolideR, 0.5 mg (Fingolimod, Osvahpharma, Tehran, Iran) is safe and efficient for Iranian MS patients.
متن کامل [PDF 352 kb]   (66 دریافت)    
نوع مطالعه: Original Article | موضوع مقاله: Neurology
دریافت: 1399/1/24 | پذیرش: 1399/6/5 | انتشار: 1400/1/12
ارسال نظر درباره این مقاله
نام کاربری یا پست الکترونیک شما:

CAPTCHA



XML   English Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Doosti R, Naser Moghadasi A, Azimi A R, Karbalai Saleh S, Etemadifar M, Shaygannejad V, et al et al et al . Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study. Caspian J Intern Med. 2021; 12 (3) :263-274
URL: http://caspjim.com/article-1-2280-fa.html

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study. 1. 1400; 12 (3) :263-274

URL: http://caspjim.com/article-1-2280-fa.html



دوره 12، شماره 3 - ( 1-1400 ) برگشت به فهرست نسخه ها
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4312